Page last updated: 2024-10-27

gabapentin and Agitation, Psychomotor

gabapentin has been researched along with Agitation, Psychomotor in 11 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"Twelve patients with moderate to severe dementia and severe behavioral disorders were treated with open-label gabapentin (200-1,200 mg/day) for 8 weeks in a prospective case-series design."9.09Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. ( Herrmann, N; Lanctôt, K; Myszak, M, 2000)
"We aimed to report our institution's experience with gabapentin therapy to manage agitation and pain in the neonatal intensive care unit (NICU) setting."7.96Gabapentin for pain, movement disorders, and irritability in neonates and infants. ( Burnsed, JC; Heinan, K; Letzkus, L; Zanelli, S, 2020)
"Our patient, a 77-year-old Czech woman with incipient vascular dementia, received gabapentin 400mg at bedtime for 6 months and showed convincing improvement."7.77Gabapentin in the treatment of dementia-associated nocturnal agitation. ( Busek, P; Buskova, J; Nevsimalova, S, 2011)
" The aim of the present study was to examine the role of Gabapentin oral solution in attenuating desflurane associated EA in children after strabismus surgery under general anesthesia."5.27The role of Gabapentin oral solution in decreasing desflurane associated emergence agitation and delirium in children after stabismus surgery, a prospective randomized double-blind study. ( Adel, G; Al Menesy, T; Badawy, AA; Badawy, YA; Kasem, SA; Mokhtar, AM; Rashwan, D, 2018)
"Twelve patients with moderate to severe dementia and severe behavioral disorders were treated with open-label gabapentin (200-1,200 mg/day) for 8 weeks in a prospective case-series design."5.09Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. ( Herrmann, N; Lanctôt, K; Myszak, M, 2000)
" The purpose of this review of the literature is to assess the interest and the limits of anticonvulsant mood stabilizers (carbamazepine, valproic acid, gabapentin, lamotrigine, topiramate, oxcarbazepine) in the treatment of the so-called "noncognitive" symptoms of dementia."4.84[Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)]. ( Pinheiro, D, 2008)
"We aimed to report our institution's experience with gabapentin therapy to manage agitation and pain in the neonatal intensive care unit (NICU) setting."3.96Gabapentin for pain, movement disorders, and irritability in neonates and infants. ( Burnsed, JC; Heinan, K; Letzkus, L; Zanelli, S, 2020)
"Our patient, a 77-year-old Czech woman with incipient vascular dementia, received gabapentin 400mg at bedtime for 6 months and showed convincing improvement."3.77Gabapentin in the treatment of dementia-associated nocturnal agitation. ( Busek, P; Buskova, J; Nevsimalova, S, 2011)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (27.27)18.2507
2000's5 (45.45)29.6817
2010's2 (18.18)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Badawy, AA1
Kasem, SA1
Rashwan, D1
Al Menesy, T1
Adel, G1
Mokhtar, AM1
Badawy, YA1
Burnsed, JC1
Heinan, K1
Letzkus, L1
Zanelli, S1
Pinheiro, D1
Buskova, J1
Busek, P1
Nevsimalova, S1
Regan, WM1
Gordon, SM1
Goldenberg, G1
Kahaner, K1
Basavaraju, N1
Rangu, S1
Low, RA1
Brandes, M1
Herrmann, N1
Lanctôt, K1
Myszak, M1
Roane, DM1
Feinberg, TE1
Meckler, L1
Miner, CR1
Scicutella, A1
Rosenthal, RN1
Bozikas, V1
Bascialla, F1
Yulis, P1
Savvidou, I1
Karavatos, A1
Megna, JL1
Devitt, PJ1
Sauro, MD1
Dewan, MJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Role of Gabapentin Oral Solution in Decreasing Desflurane Associated Emergence Agitation and Delirium in Children After Strabismus Surgery: A Prospective Randomized Double-blind Study[NCT03347916]75 participants (Anticipated)Interventional2017-01-05Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for gabapentin and Agitation, Psychomotor

ArticleYear
[Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)].
    L'Encephale, 2008, Volume: 34, Issue:4

    Topics: Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dementia; Fructose; Gabap

2008

Trials

3 trials available for gabapentin and Agitation, Psychomotor

ArticleYear
The role of Gabapentin oral solution in decreasing desflurane associated emergence agitation and delirium in children after stabismus surgery, a prospective randomized double-blind study.
    BMC anesthesiology, 2018, 06-20, Volume: 18, Issue:1

    Topics: Administration, Oral; Anesthesia, General; Anesthetics, Inhalation; Child; Child, Preschool; Desflur

2018
Effectiveness of gabapentin for the treatment of behavioral disorders in dementia.
    Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:1

    Topics: Acetates; Aged; Aged, 80 and over; Amines; Anti-Anxiety Agents; Behavioral Symptoms; Cyclohexanecarb

2000
Gabapentin's effect on agitation in severely and persistently mentally ill patients.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:1

    Topics: Acetates; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty

2002

Other Studies

7 other studies available for gabapentin and Agitation, Psychomotor

ArticleYear
Gabapentin for pain, movement disorders, and irritability in neonates and infants.
    Developmental medicine and child neurology, 2020, Volume: 62, Issue:3

    Topics: Analgesics; Female; Gabapentin; Humans; Infant; Infant, Newborn; Intensive Care Units, Neonatal; Mal

2020
Gabapentin in the treatment of dementia-associated nocturnal agitation.
    Medical science monitor : international medical journal of experimental and clinical research, 2011, Volume: 17, Issue:12

    Topics: Aged; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Darkness; Dementia; Female; Gabapent

2011
Gabapentin for behavioral agitation in Alzheimer's disease.
    Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:1

    Topics: Acetates; Aged; Alzheimer Disease; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Admini

1997
Gabapentin for disruptive behaviour in an elderly demented patient.
    Drugs & aging, 1998, Volume: 13, Issue:2

    Topics: Acetates; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dementia; D

1998
Gabapentin for the management of agitation.
    Journal of clinical psychopharmacology, 1999, Volume: 19, Issue:5

    Topics: Acetates; Aggression; Amines; Cyclohexanecarboxylic Acids; GABA Agonists; Gabapentin; gamma-Aminobut

1999
Treatment of dementia-associated agitation with gabapentin.
    The Journal of neuropsychiatry and clinical neurosciences, 2000,Winter, Volume: 12, Issue:1

    Topics: Acetates; Aged; Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Cyclohexanecarboxylic

2000
Gabapentin for behavioral dyscontrol with mental retardation.
    The American journal of psychiatry, 2001, Volume: 158, Issue:6

    Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Drug Th

2001